Finance
Eli Lilly stock gets bump after results for its mid-stage diabetes drug trial shows positive results (LLY)
- On Thursday, pharma giant Eli Lilly and Co. announced positive results in a mid-stage trial for its experimental new diabetes drug. The company’s stock rose 3% on the news.
- The drug significantly reduced blood sugar levels and promoted weight loss in patients with type 2 diabetes.
- The late-stage trial for this drug is expected to be completed in 2021.
- This drug has to potential to boost Lilly’s growing portfolio of drugs extending across the areas of oncology, cardiovascular, diabetes, critical care, neuroscience, men’s health and musculoskeletal fields.
Continue Reading
-
Business7 days ago
This camera trades pictures for AI poetry
-
Business6 days ago
TikTok Shop expands its secondhand luxury fashion offering to the UK
-
Business7 days ago
Boston Dynamics unveils a new robot, controversy over MKBHD, and layoffs at Tesla
-
Business5 days ago
UnitedHealth says Change hackers stole health data on ‘substantial proportion of people in America’
-
Business5 days ago
Mood.camera is an iOS app that feels like using a retro analog camera
-
Business4 days ago
Tesla’s new growth plan is centered around mysterious cheaper models
-
Entertainment5 days ago
Furious Watcher fans are blasting it as ‘greedy’ over paid subscription service
-
Business3 days ago
Xaira, an AI drug discovery startup, launches with a massive $1B, says it’s ‘ready’ to start developing drugs